BioNxt Solutions: Innovative drug films put to the test
Not every groundbreaking medical innovation requires the development of an entirely new active ingredient. Often, it is a smarter, more patient-friendly method of administration that makes the decisive difference. This is precisely the approach taken by the Canadian biotech company. BioNxt Solutions is focused on developing thin drug films that dissolve easily in the mouth.
The focus here is on the lead project, BNT23001, a novel formulation based on cladribine, a clinically proven, established active ingredient used, among other things, to treat certain relapsing forms of multiple sclerosis.
Targeted administration without liquids and without the difficulty of swallowing tablets offers tangible added value, particularly for patients with chronic swallowing difficulties. The company recently reported the successful completion of the production of around 1,500 clinical trial films, manufactured in strict accordance with pharmaceutical GMP quality standards, while the formal clinical trial application had already been submitted via the central European CTIS portal.
A planned bioequivalence comparison with the established reference product Mavenclad is now intended to clarify, in particular, how the body absorbs the active ingredient under real-world conditions and what effective concentrations are achieved, with fundamental parameters such as safety and tolerability also in focus.
Beyond the MS programme, BioNxt is advancing an ambitious semaglutide film programme together with its German development partner Gen-Plus. The development programme launched in the spring currently involves demanding formulation work, analytical procedures and basic feasibility testing.
BioNxt is not only focusing on individual drug candidates, but is pursuing a broader development approach with its technology platform. In addition to innovative orally dissolving films (ODFs) and transdermal patches, the company is working on improved oral drug formulations and targeted drug delivery systems for cancer therapy. Initial laboratory results are encouraging, but their significance has yet to be demonstrated in further development phases.
With a current share price of about CAD 0.26 and around 136.09 million shares outstanding, BioNxt’s market capitalisation amounts to a modest CAD 35 million.
Bayer: Share price at a yearly high
Bayer generates its revenue across a broad range of prescription pharmaceuticals, over-the-counter healthcare products and its global agricultural business. In the sensitive pharmaceuticals sector, it is crucial that newer, dynamic growth drivers offset the massive revenue declines of older blockbuster drugs whose patents have expired.
Thanks to positive business performance in its pharmaceuticals division, Bayer is more optimistic about the current financial year and has raised its earnings forecast. Adjusted EBITDA is now expected to reach EUR 9.8 billion to EUR 10.3 billion, with both ends of the range EUR 200 million above the previous guidance. Growth drivers include, in particular, the relatively new medicines Nubeqa for treating prostate cancer and Kerendia for protecting the kidneys and heart. Both products recorded significant revenue increases in the third quarter. Overall, the pharmaceuticals division increased its adjusted operating profit by almost a quarter.
By contrast, the weaker agricultural business, with a significant decline in earnings, and the ongoing litigation in the US weighed on performance. The glyphosate lawsuits in particular remain a source of uncertainty, but the recent victory in a US jury trial is encouraging.
Novo Nordisk: Enormous earnings power
The Danish specialist in diabetes and obesity treatments shows that innovative, alternative dosage forms can make a big difference in the pharmaceutical sector. In the third quarter alone, the newly launched oral Wegovy tablet generated DKK 5.39 billion in revenue. This underscores strong patient demand for convenient, needle-free treatment options.
Supported by this continuing boom, Novo Nordisk raised its financial outlook and narrowed its full-year expectations for adjusted revenue and operating profit to a range of minus 2% to plus 2% at constant exchange rates. In the third quarter, group revenue climbed to DKK 79.20 billion, while adjusted operating profit rose by a disproportionately strong 27% at constant exchange rates. Free cash flow in the first nine months stood at DKK 83.8 billion.
Conclusion
Novo Nordisk is the undisputed industry leader, able to profitably expand its global dominance in the metabolic therapies segment despite growing competitive pressure. The Danish company also demonstrates how successful innovative and alternative dosage forms can be. This is precisely where BioNxt Solutions comes in. In addition to innovative orally dissolving films (ODFs) and transdermal patches, the company is working on improved oral drug formulations and targeted drug delivery systems for cancer therapy. This gives the Canadian company considerable leverage given a market capitalisation of just CAD 35 million. A strong pharmaceuticals business is fuelling optimism at Bayer. Its shares are trading at a yearly high.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
